|Articles|January 11, 2023
- Pharmaceutical Executive: January 2023
- Volume 43
- Issue 01
What We Foresee in ’23: Pharm Exec’s Annual Industry Outlook
Exploring the most relevant topics affecting the biopharma industry as the new year gets underway—ranging from trends ripe with risk and opportunity to those driving more definitive growth opportunities in patient care.
Advertisement
Articles in this issue
over 3 years ago
Key Factors Attributing to a Successful Product Launchover 3 years ago
Closing the Digital Gap: FDA’s Oversight of Social Mediaover 3 years ago
Sales-Rep Compensation: Adding Long-Term Incentives to Mixover 3 years ago
Co-creating New Innovationsover 3 years ago
The Potential Impact of the IRAover 3 years ago
Patient Hubs Continue Growthover 3 years ago
Social Media’s Complex Climbover 3 years ago
Industry Workforce Seeks Clarityover 3 years ago
Cybersecurity Threats & PharmaAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report
3
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
4
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
5